Dianthus Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Dianthus Therapeutics Inc.
- Former names
- Magenta Therapeutics, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- New York
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- DNTH
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001690585
Board of directors
-
Alison Frances Lawton · DirectorSince 2023
-
Anne McGeorge · DirectorSince 2023
-
David Roy Witzke · DirectorSince 2024
-
Jonathan Violin · DirectorSince 2023
-
Lei Meng · DirectorSince 2023
-
Leon O. Moulder Jr. · DirectorSince 2023
-
Marino Garcia · Director · CEO AND PRESIDENTSince 2023
-
Michael David Gregory · DirectorSince 2024
-
Paula Soteropoulos · DirectorSince 2023
- Since 2023
-
Simon Read · DirectorSince 2025
-
Steven J. Romano · DirectorSince 2024
-
Sujay Kango · DirectorSince 2025
- Since 2023
Chief executives
Marino Garcia
· CEO and President
Since September 2023
Director election results
Annual meeting of May 21, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
80.6%
-
98.9%
-
99.0%
Board connections
9 of this board's directors also sit on 17 other boards.
- via Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
- via Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
- via Alison Frances Lawton, Peter Evan Harwin and Tomas Kiselak
- via Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
- via Leon O. Moulder Jr., Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via Peter Evan Harwin and Tomas Kiselak
- via Marino Garcia
- via Peter Evan Harwin
- via Peter Evan Harwin
- via Sujay Kango
- via Alison Frances Lawton
- via Paula Soteropoulos
- via Anne McGeorge
- via Alison Frances Lawton
- via Leon O. Moulder Jr.
- via Paula Soteropoulos
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $71,203,579
- 66 sales by 8 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 17, 2026 | CARR EDWARD Officer (CHIEF ACCOUNTING OFFICER) | Option exercise | +20,000 | $17.88 | $357,600 |
| Sep 17, 2026 | CARR EDWARD Officer (CHIEF ACCOUNTING OFFICER) | Open-market sale | −7,928 | $100.43 | $796,209 |
| Sep 17, 2026 | CARR EDWARD Officer (CHIEF ACCOUNTING OFFICER) | Open-market sale | −6,771 | $101.37 | $686,376 |
| Sep 17, 2026 | CARR EDWARD Officer (CHIEF ACCOUNTING OFFICER) | Open-market sale | −3,501 | $102.39 | $358,467 |
| Sep 17, 2026 | CARR EDWARD Officer (CHIEF ACCOUNTING OFFICER) | Open-market sale | −1,100 | $103.20 | $113,520 |
| Sep 17, 2026 | CARR EDWARD Officer (CHIEF ACCOUNTING OFFICER) | Open-market sale | −700 | $104.39 | $73,073 |
| Sep 1, 2026 | Randhawa Simrat Officer (EVP, Head of R&D) | Option exercise | +7,500 | $17.88 | $134,100 |
| Sep 1, 2026 | Randhawa Simrat Officer (EVP, Head of R&D) | Option exercise | +6,249 | $21.77 | $136,041 |
| Sep 1, 2026 | Randhawa Simrat Officer (EVP, Head of R&D) | Option exercise | +9,375 | $22.07 | $206,906 |
| Sep 1, 2026 | Randhawa Simrat Officer (EVP, Head of R&D) | Open-market sale | −2,600 | $105.19 | $273,494 |
| Sep 1, 2026 | Randhawa Simrat Officer (EVP, Head of R&D) | Open-market sale | −7,215 | $106.25 | $766,594 |
| Sep 1, 2026 | Randhawa Simrat Officer (EVP, Head of R&D) | Open-market sale | −13,309 | $106.74 | $1,420,603 |
| Aug 19, 2026 | Simon Read Director | Option exercise | +2,778 | $18.36 | $51,004 |
| Aug 19, 2026 | Simon Read Director | Open-market sale | −2,778 | $117.55 | $326,554 |
| Aug 13, 2026 | Veness Adam M Officer (SVP, General Counsel and Sec.) | Option exercise | +15,000 | $18.17 | $272,550 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.